Aprea Therapeutics, Inc. (APRE) vs CNS Pharmaceuticals, Inc. (CNSP)
A side-by-side comparison of Aprea Therapeutics, Inc. and CNS Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
APRE
Aprea Therapeutics, Inc.
$0.64HealthcareDelayed quote: Oct 6, 2026, 2:20 PM EDT
CNSP
CNS Pharmaceuticals, Inc.
$5.44HealthcareDelayed quote: Oct 6, 2026, 2:03 PM EDT
Total return — APRE vs CNSP
growth of $100 · dividends reinvested · last 7yAPRE -99.9% (-61.1%/yr)CNSP -100.0% (-85.6%/yr)APRE compounded faster over this window
Log scale — wide-divergence pair
APRE CNSP
APRE vs CNSP: by the numbers
- •CNSP is the larger company ($8M vs $8M market cap).
Metrics side by side
Valuation
| Metric | APRE | CNSP |
|---|---|---|
| P/B ratio | 0.21 | 0.44 |
Profitability
| Metric | APRE | CNSP |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -31.99% | -91.75% |
| ROIC | -33.73% | -92.94% |
Growth (annualized)
| Metric | APRE | CNSP |
|---|---|---|
| Total return CAGR (5Y) | -63.30% | -91.63% |
Frequently asked
- How have APRE and CNSP total returns compared?
- Over the past 5 years, APRE delivered -63.30% and CNSP delivered -91.63% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.